Share: Facebook Twitter LinkedIn
Activity Provided By:


Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Access Activity

Overview / Abstract:

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging therapies into your treatment plans to best meet the needs of your patients and get the answers you need about MDS classification and risk assessment.


Oct 27, 2024


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Daniel Pollyea, MD, MS
Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, CO

Sponsors / Supporters / Grant Providers

Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).

The organizing committee wishes to express appreciation to the following company for their commitment to continuing medical education by providing an educational grant in support of this educational activity:

Gilead Sciences, Inc.

Keywords / Search Terms

ACHL Pollyea, DiNardo, hematology, pathology, oncology, transfusion, MDS, myelodysplastic syndromes, high-risk MDS, HR-MDS, CD47, immune surveillance, mechanism of action, MOA, cytopenia, hemoglobin, dysplasia, cytogenetic testing, cytogenetics, karyotype, multidisciplinary, biopsy, neutropenia, myeloid neoplasm, hematopoiesis, bone marrow, hypercellularity, mutational testing, NGS, next generation sequencing, hypomethylating agent, HMA, azacitidine, AZA, decitabine, DAC, cedazuradine, macrocytic anemia, anemia, Revised International Prognostic Scoring System, IPSS-R, IPSS-molecular, IPSS-M, TP53, magrolimab, sabatolimab, venetoclax Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map